Cefodox

Quick links to important sections

Cefodox

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefodox

Property Description
Active Ingredient Cefpodoxime proxetil
Form Film-coated tablets, Granules for oral suspension
Pharmacological Class Third-generation Cephalosporin (Antibiotic)
Common Use (General) Treating susceptible Bacterial infections
Origin Synthetic Prodrug

What Type of Medicine is Cefodox? (Identity and Classification)

Cefodox is a synthetic broad-spectrum antibiotic used for systemic application and is available only as a prescription-only medicine (Rx status). It belongs to the cephalosporin family, specifically classified as a third-generation derivative within the broader group of beta-lactam antibiotics. This classification signifies that the drug is designed to address a wide range of common and complex bacterial infections throughout the body, providing a targeted defense against susceptible pathogens.


Cefpodoxime: Understanding the Active Ingredient and Form

The active ingredient in Cefodox is cefpodoxime proxetil. This compound is classified as a prodrug, meaning it is initially inactive when taken but is rapidly converted in vivo to its true therapeutic agent, cefpodoxime. For oral administration, Cefodox is supplied in two primary dosage forms: film-coated tablets and granules for oral suspension. The availability of the granules for oral suspension formulation specifically caters to pediatric patient groups and those who have difficulty swallowing tablets. The necessity of the prodrug structure is a chemical strategy intended to optimize the medicine's absorption from the digestive tract to ensure effective delivery for systemic use.


How Cefodox Exerts Its Antibacterial Purpose

Cefodox works through a potent bactericidal action, which means it is designed to kill susceptible bacteria rather than just inhibiting their growth. This bactericidal effect is achieved by directly disrupting the structural integrity of the bacterial cell. The core function is to specifically halt the bacteria's ability to build and maintain their protective outer cell wall, leading to the irreversible breakdown and death of the microbial cell and contributing to the resolution of the bacterial infection.

Regulatory References

  1. National Institutes of Health, NIH

What side effects are possible with Cefodox?

Possible Side Effects and Safety Information: Cefodox

Cefodox (cefpodoxime proxetil) is associated with an established safety profile based on regulatory documentation. The most common adverse reactions include gastrointestinal disturbances such as diarrhea, nausea, vomiting, and abdominal pain, as well as headache and skin rash.

Serious and Clinically Significant Adverse Reactions

The most clinically significant risks include severe hypersensitivity reactions, such as anaphylaxis, which mandate immediate discontinuation of the medication. Other serious reactions documented are pseudomembranous colitis (severe, watery, or bloody diarrhea, often associated with C. difficile overgrowth), severe bullous skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), and blood disorders (e.g., neutropenia, thrombocytopenia).

Safety Restrictions and Monitoring

Contraindication exists for patients with a known immediate-type hypersensitivity to cefpodoxime or any cephalosporin antibiotic. Caution is required for patients with a history of penicillin allergy due to the potential for cross-sensitivity.

Population-specific safety notes indicate the dose must be reduced in patients with moderate to severe renal impairment due to decreased elimination. The drug is excreted in human milk, and its use during pregnancy requires careful assessment of risk versus benefit. Prolonged use necessitates monitoring for the overgrowth of non-susceptible organisms. The medication may affect certain laboratory tests, including the Coombs' test and urine glucose assays.

Overdose and Emergency Response

Cefodox Overdose and When to Seek Help

Regulatory documentation specifies that an overdose of Cefodox (cefpodoxime proxetil) is primarily associated with amplified gastrointestinal distress. Documented manifestations include severe nausea, vomiting, diarrhea, and epigastric distress. A more serious, officially documented outcome is the potential for Central Nervous System (CNS) effects, which can present as seizure activity, confusion, consciousness disorders, or abnormal movements. These severe neurological effects are described as usually reversible once the drug concentration in the body has decreased.


Mandatory Emergency Actions

It is officially mandated that any suspected overdose requires immediately seeking emergency medical attention. Individuals must contact emergency services or a Poison Control Center. Urgent medical help is required for life-threatening symptoms such as collapse, seizure, severe trouble breathing, or if the person cannot be awakened.

Overdose Management and Risk

The official management procedure is symptomatic and supportive therapy, given the lack of a specific antidote. Patients with impaired renal function are officially noted as a population at increased risk for developing severe toxic reactions, including encephalopathy, due to the potential for high and prolonged serum drug concentrations. In these cases, hemodialysis is documented as a procedure that may be utilized to aid in the removal of the drug from the system.

Therapeutic Uses of Cefodox

Cefodox (cefpodoxime proxetil) is a third-generation cephalosporin antibiotic commonly used to help with symptoms that create noticeable physiological strain when caused by susceptible bacterial infections. The medicine is applied across domains where additional symptomatic support is needed, and generally contributes to easing the overall symptom load.

Cefodox may be part of symptomatic management in clinical settings that involve acute or unstable symptom patterns. This medication is relevant for easing symptoms related to infections such as uncomplicated urinary tract infections, community-acquired pneumonia, acute otitis media, certain skin and soft tissue infections, bacterial sinusitis, bronchitis, and pharyngitis. It helps address symptom clusters that may become intense or disruptive, including fever, severe sore throat, and localized pain.

“The primary benefit of this treatment is the supportive relief it offers during difficult episodes, assisting with maintaining functional stability.”

Cefodox assists with maintaining functional stability during symptomatic phases, providing support that helps ease the overall symptom burden.

Quick Fact: May assist with Localized Pain and Fever

Regulatory References

  1. NIH MedlinePlus overview of Cefpodoxime uses

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Cefpodoxime Proxetil (Cefodox)

Cefpodoxime Proxetil eligibility is strictly defined by regulatory bodies based on patient factors, existing conditions, and age.


Populations Excluded (Contraindications)

Classification Population Constraint Type
Formal Contraindication Patients with known hypersensitivity (allergy) to Cefpodoxime or to any antibiotic in the cephalosporin class. Immunological
Formal Contraindication Patients with a history of a severe or immediate-type hypersensitivity reaction (e.g., anaphylaxis) to penicillin or other beta-lactam antibiotics. Immunological
Specific Exclusion Individuals with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (for specific formulations containing lactose). Metabolic

Populations Requiring Restricted or Conditional Use

  • Renal Impairment: Patients with severe kidney dysfunction (low creatinine clearance) must have the drug's total daily dose reduced to prevent high antibiotic concentrations.
  • Infants: Use is not established for infants younger than two months of age; safety and efficacy data are insufficient for this group.
  • Pregnancy and Lactation: Use during pregnancy is advised only if clearly needed. For breastfeeding mothers, the risk of drug excretion into breast milk must be weighed against the importance of the medicine to the mother, potentially requiring discontinuation of nursing.
  • Gastrointestinal History: Use requires caution in patients with a history of gastrointestinal disease, particularly colitis.

Patients who do not fall into these excluded or restricted categories, including adults, adolescents, and children two months and older, may be considered eligible.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Cefodox (Cefpodoxime proxetil) primarily affect its absorption and elimination, which may necessitate adjustments in the timing of medication administration or increased monitoring.


Exposure-Modifying Interactions

Cefodox requires an acidic environment for proper absorption. Substances that raise stomach pH will reduce the drug's bioavailability, potentially leading to lower effectiveness. Conversely, agents that interfere with its excretion can increase its concentration in the bloodstream.

Interacting Product Category Effect on Cefodox Exposure Clinical Constraint
H2-Blockers & Antacids Reduced Cmax and AUC (Reduced Absorption) Separate administration by 2 to 3 hours.
Probenecid Increased Cmax and AUC (Inhibited Renal Excretion) May require close observation.
Food (Tablets) Increased Absorption Tablets should be taken with a meal.

Pharmacodynamic and Safety-Related Interactions

Official regulatory information describes potential additive effects when Cefodox is co-administered with specific drug classes:

  • Oral Anticoagulants (e.g., Warfarin): May enhance the anticoagulant effect, requiring frequent monitoring of coagulation parameters (INR).
  • Potentially Nephrotoxic Drugs: Concomitant use with other drugs known to cause kidney damage necessitates monitoring of renal function due to a potentially increased risk of changes in kidney function.

Mechanism of Action

Cefodox is a beta-lactam agent that acts by targeting the machinery responsible for the final stages of bacterial cell wall construction. Its primary action involves binding to and inactivating bacterial penicillin-binding proteins (PBPs), a class of essential transpeptidases and carboxypeptidases located within the bacterial cell membrane.

The specific interaction occurs at the active site of the PBPs, inhibiting their ability to catalyze the final cross-linking of peptidoglycan chains, which provides structural rigidity to the cell wall. By preventing this transpeptidation step, Cefodox causes the synthesis of a defective and unstable peptidoglycan layer. The resulting cell wall instability leads directly to high osmotic pressure and subsequent bacterial lysis and destruction. This cascade modulates the physiological status by causing a measurable reduction in the active bacterial population within the biological system.

Dosage and Administration Information

The administration of Cefodox (cefpodoxime proxetil) is structured by guidelines that define the route, frequency, and relationship to food to ensure effective systemic delivery of the active agent. This medicine is strictly for oral administration, available as film-coated tablets (100 mg and 200 mg) and granules for oral suspension.

The dosing schedule typically follows a twice-daily frequency, with a standard interval of 12 hours between doses. Adult dosing ranges from 100 mg to 400 mg per dose, with a single 200 mg dose indicated for specific uncomplicated infections. The total duration of use is fixed and predetermined, varying between 5 to 14 days based on the regimen.

A key procedural constraint involves drug absorption: film-coated tablets must be taken with food to enhance systemic delivery. Conversely, the oral suspension may be administered without regard to meal timing. When using the suspension, the container must be shaken well prior to measurement. If a dose is missed, it should be taken as soon as possible unless nearly time for the next dose; double doses are to be avoided.

Specific modifications to the standardized schedule are required for compromised kidney function. For patients with severely reduced renal clearance (CrCl le 29 mL/min), the dosing interval is extended to 24 hours. Patients on hemodialysis receive the dose three times per week, after each dialysis session. No adjustment to the dosing is specified for patients with hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Cefodox

Evidence for Use in Acute Ear and Throat Infections

Research has explored Cefodox ( cefpodoxime proxetil) in relation to common episodic infections, including Acute Otitis Media (AOM), which affects the middle ear, and Pharyngitis/Tonsillitis (strep throat). Research exploring short-term symptom changes primarily consisted of Randomized Controlled Trials (RCTs). These studies were designed to compare Cefodox against other established antibiotics, such as amoxicillin/clavulanic acid or penicillin.

For AOM, studies primarily focused on pediatric patients—infants and children—and research examined how symptoms change over time. The trials also monitored the bacteriological eradication rate, which is a measurement of the clearance of the specific bacteria causing the infection. Similarly, research for Pharyngitis explored the rates of symptom resolution and the bacteriological eradication rate for Streptococcus pyogenes from the throat in both children and adults. Findings describe patterns observed in the studies that were generally consistent with the comparator drugs for these short-term outcomes.

Research for Acute Lower Respiratory and Skin Infections

Cefodox was examined in comparative clinical trials focusing on acute lower respiratory issues, including Community-Acquired Pneumonia (CAP) and Acute Exacerbations of Chronic Bronchitis (AECB). Studies also explored its use in Uncomplicated Skin and Skin Structure Infections (SSSI), such as cellulitis or simple wound infections. These trials were typically conducted during periods of increased symptom activity and focused on adult patients with infections not requiring initial inpatient care.

For respiratory infections, research examined outcomes related to systemic or functional imbalance, specifically looking at patterns in symptom change, such as cough and fever. For SSSI, research included dose-ranging studies, and findings indicated that the measured response was associated with the specific dosage used. Studies observed that the surgical drainage of any associated abscesses was required for assessment in these types of infections.

What Remains Uncertain in the Evidence Base

Evidence is limited for long-term follow-up in most indications, as the focus of the research was on acute treatment. Long-term effects are not fully established, meaning there is limited information for outcomes related to sustained prevention of recurrence or chronic disease management. Specific data related to the treatment of infections caused by beta-lactamase-producing strains of H. influenzae have been reported as inconsistent in some studies, meaning certainty remains low in this specific context.

Data for certain groups remain insufficient. For instance, the research for uncomplicated gonorrhea indicated that data for infections in the rectal area in male patients or for pharyngeal infections are limited, as these specific sites were generally excluded from the primary efficacy studies. The evidence highlights what is known—and what is still uncertain—about the drug's performance under specific conditions.

Frequently Asked Questions (FAQ)

Common questions about Cefodox (FAQ)


Q: How quickly should I start feeling better after taking Cefodox?

A: Studies and official information indicate that the active form of the drug typically reaches its highest concentration in the bloodstream approximately two to three hours after oral administration. The time required for symptoms to begin changing varies across individuals and depends on the specific type and severity of the infection.


Q: How long does Cefodox stay in your system after the last dose?

A: Cefodox is primarily cleared from the body by the kidneys. In healthy adults, the elimination half-life is around 2.4 hours. Based on the half-life, the majority of the drug is typically cleared from the body within about a day, although this can vary depending on individual factors.


Q: Can Cefodox cause headaches or dizziness?

A: Yes, official product information lists headache as a common adverse reaction associated with Cefodox. Dizziness has also been reported as a possible, less common side effect.


Q: Can Cefodox affect birth control pills?

A: Regulatory documents suggest that antibiotics, including Cefodox, may potentially reduce the effectiveness of oral contraceptives that contain ethinyl estradiol in some individuals. Regulatory notes indicate that using additional non-hormonal contraception may be appropriate while undergoing treatment, particularly if there are concerns.


Q: Is Cefodox effective against all types of bacterial infections?

A: Cefodox is classified as a broad-spectrum antibiotic, meaning it is active against a wide variety of bacteria. However, it is only prescribed for infections specifically caused by susceptible organisms listed in the prescribing information. It will not work against infections caused by viruses (such as the flu) or bacteria that are resistant to the medicine.


Q: Can Cefodox be crushed or chewed if someone has trouble swallowing pills?

A: Cefpodoxime proxetil tablets are film-coated and should generally be swallowed whole, not crushed or chewed. If swallowing tablets is a concern, the medication is also available in an oral suspension (liquid) form.


Q: What happens if I accidentally miss a dose of Cefodox?

A: The official product instructions describe that a missed dose may be taken as soon as it is remembered, unless the next dose is due shortly. The instructions also specify that double doses should be avoided.


Q: Does Cefodox interact with common allergy medications?

A: Regulatory documents primarily focus on interactions with medications that reduce stomach acid, such as H2-blockers and antacids. General allergy medications (like common antihistamines) are not typically highlighted as having a clinically significant interaction requiring adjustment in major official summaries.


Q: Can Cefodox cause fatigue or tiredness?

A: While not listed as one of the most common side effects, post-marketing reports indicate that non-specific symptoms such as asthenia (weakness) or sleep disturbances, including nervousness, may occur during treatment.


Q: What conditions does Cefodox treat besides respiratory tract infections?

A: Cefodox is approved to treat a variety of bacterial infections. Beyond respiratory tract issues, its indications include acute otitis media (middle ear infection), uncomplicated urinary tract infections (UTIs), uncomplicated skin and skin structure infections, and uncomplicated gonorrhea.


Q: What kind of research supports the use of Cefodox for pneumonia?

A: The use of Cefodox for Community-Acquired Pneumonia (CAP) is supported by clinical trials, including randomized controlled trials (RCTs). The findings in these trials measured outcomes like symptom resolution and were generally comparable to those of the other antibiotics tested.


Q: Can Cefodox cause insomnia or trouble sleeping?

A: Official information indicates that insomnia (trouble sleeping) and other central nervous system effects, such as nervousness or strange dreams, have been reported as adverse reactions in clinical use.


Q: Can Cefodox be taken with cold and flu medicine?

A: Cefodox is known to interact with stomach acid reducers. However, general cold and flu medicines are not typically listed in the official documentation as being associated with a clinically significant interaction that requires dose changes.


Q: Is it possible to take Cefodox for too long?

A: The recommended duration of therapy is typically short and pre-determined. Prolonged use is addressed in regulatory notes as it carries a risk of the overgrowth of non-susceptible organisms.


Q: Does Cefodox affect blood sugar levels?

A: Official information does not indicate that Cefodox alters blood sugar levels. However, it is known to cause a false-positive reaction for glucose in the urine when certain copper sulfate-based tests (like Benedict's or Fehling's solution) are used, which is a known laboratory test interference.


Q: What are the signs that Cefodox might not be working for my infection?

A: Regulatory warnings describe that potential signs of treatment failure, or a new infection (superinfection), include the worsening of existing symptoms or the development of new health problems. Severe, persistent, watery, or bloody diarrhea is noted in regulatory documents as a clinically significant adverse reaction that may indicate a serious C. difficile infection.

How should Cefodox be stored and disposed of?

How to Store and Dispose of Cefodox

Cefodox (cefpodoxime proxetil) storage must strictly follow regulatory guidance to maintain stability and effectiveness.


Official Storage Requirements

Dosage Form Temperature Range Stability/Handling
Tablets / Unreconstituted Powder Controlled Room Temperature (20 C to 25 C) Store in original, tightly closed container; protect from moisture.
Reconstituted Oral Suspension Refrigeration (2 C to 8 C) Do not freeze; discard any unused portion after 14 days.

Child Safety and Disposal

The medicine must be stored out of the sight and reach of children.

Unused or expired Cefodox must be disposed of according to local requirements. Disposal should not occur via household wastewater (sink or toilet).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefodox found in:

A-Z Index: